Oslo Universitetssykehus HF

The Dept. of Hematology at Oslo University Hospital conducts extensive research on blood‑cancer disorders such as leukemia, lymphoma and multiple myeloma, aiming to test innovative targeted agents and improve stem‑cell transplant outcomes.

• Acute lymphoblastic leukemia
• Chronic myeloid leukemia
• Mantle cell lymphoma
• Plasma cell myeloma
• Myelodysplastic syndromes

Trials evaluate safety, efficacy and biomarkers to personalize therapy for patients with high‑risk hematologic malignancies.

Research spans major solid cancers, including non‑small cell lung cancer, breast cancer, melanoma and gastrointestinal malignancies, with a focus on novel immunotherapy combinations and precision‑medicine approaches.

• Advanced NSCLC with EGFR or KRAS mutations
• HER2‑positive breast cancer
• Metastatic melanoma
• KRAS‑mutant colorectal cancer
• Gastrointestinal stromal tumor (KIT‑mutated)

The goal is to enhance survival and quality of life by integrating targeted drugs, checkpoint inhibitors and anti‑angiogenic agents.

The site advances care for cardiovascular conditions such as atherosclerotic cardiovascular disease and atrial fibrillation, while also addressing metabolic disorders like type‑2 diabetes and familial hypercholesterolemia.

• Aortic stenosis
• Persistent atrial fibrillation
• Chronic heart failure
• Familial hypercholesterolemia
• Type‑2 diabetes mellitus

Ongoing studies compare antithrombotic strategies, evaluate new lipid‑lowering therapies and explore metabolic control to reduce cardiovascular risk.

A broad portfolio targets autoimmune and inflammatory disorders, including Crohn’s disease, ulcerative colitis, systemic lupus erythematosus and skin conditions such as hidradenitis suppurativa.

• Crohn’s disease
• Ulcerative colitis
• Systemic lupus erythematosus
• Psoriatic arthritis
• Hidradenitis suppurativa

Trials aim to determine the effectiveness of new biologics, JAK inhibitors and other immune‑modulating agents in achieving remission and improving patient outcomes.

The department investigates brain and nerve diseases, focusing on Alzheimer’s disease, amyotrophic lateral sclerosis and multiple sclerosis, with the purpose of testing disease‑modifying therapies and supportive interventions.

• Alzheimer’s disease
• Amyotrophic lateral sclerosis
• Multiple sclerosis
• Narcolepsy with cataplexy
• Cognitive impairment

Research evaluates safety, functional benefits and biomarkers to guide future treatment strategies for neurodegenerative conditions.

Specialized studies address rare childhood diseases such as achondroplasia, ataxia‑telangiectasia, Duchenne muscular dystrophy and high‑risk neuroblastoma, seeking novel gene‑targeted and enzyme‑replacement approaches.

• Achondroplasia
• Ataxia telangiectasia
• Duchenne muscular dystrophy
• High‑risk neuroblastoma
• PIK3CA‑related overgrowth spectrum

Early‑phase trials assess safety, tolerability and preliminary efficacy of emerging therapies for these genetically driven conditions.